Search Options Stock News and Analysis from Schaeffer's

Incyte Stock Eyes Worst Day Since 2018 After Trial Results

https://www.schaeffersresearch.com/content/news/2025/03/17/incyte-stock-eyes-worst-day-since-2018-after-trial-results

3/17/2025 10:44 AM

Incyte Corp (NASDAQ:INCY) stock is down 11.4% to trade at $60.16 at last glance, after the pharmaceutical company's phase three trial data for its skin disease treatment showed it was only effective ...

Biotech Roundup: 3 Stocks to Watch

https://www.schaeffersresearch.com/content/news/2024/12/11/biotech-roundup-3-stocks-to-watch

12/11/2024 3:35 PM

Most recently in the ever-growing biotech industry, investors are musing over potential changes to the sector after President-elect Donald Trump picked Martin “Marty” Makary to be the U.S. Food and D...

FDA Rejection Pushes Incyte Stock Sharply Lower

https://www.schaeffersresearch.com/content/news/2023/03/24/fda-rejection-pushes-incyte-stock-sharply-lower

3/24/2023 11:05 AM

The shares of Incyte Corporation ( NASDAQ:INCY) are down 5.3% at $68.33 at last check, after the U.S. Food and Drug Administration (FDA) failed to approve the extended-release version of the compan...

Puts Active After RBC Downgrades Incyte Stock

https://www.schaeffersresearch.com/content/options/2019/04/03/puts-active-after-rbc-downgrades-incyte-stock

4/3/2019 2:21 PM

The shares of Incyte Corporation (NASDAQ:INCY) are down 2.8% to trade at $84.30, after RBC downgraded the biotech name to "sector perform" from "outperform." The analyst in coverage doesn't see any mo...

https://www.schaeffersresearch.com/content/options/2018/10/19/calls-popular-as-incyte-stock-cheers-cancer-drug-data

10/19/2018 2:19 PM

Earlier today, Incyte Corporation (NASDAQ:INCY) reported upbeat results from its mid-stage study of Capmatinib, the company's lung cancer treatment sponsored by Novartis (NOVN). Incyte Corporation sa...

PEOPLE ALSO SEARCH FOR